Initial phase of anthracycline cardiotoxicity involves metabolic switch and activation of cardiac fibroblasts

Back

ESC Professional Premium Access

Initial phase of anthracycline cardiotoxicity involves metabolic switch and activation of cardiac fibroblasts

Session: Cardiotoxicity of drugs and other therapies

Topic: Cardiotoxicity of Drugs and Other Therapies

Speaker: Associate Professor K. Urbanek (Naples, IT)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Associate Professor Konrad Urbanek

University of Naples Federico II, Naples (Italy)

0 follower

6 more presentations in this session

Pre-diabetes is associated with increased cardiac events in cancer patients prescribed anthracyclines

Speaker: Doctor I. Cheang (Nanjing, CN)

Prognostic value of 6-minute walking test for early prediction of doxorubicin induced cardiotoxicity

Speaker: Mrs G. Muckiene (Kaunas, LT)

Usefulness of the baseline risk assessment guidelines to predict cancer therapy-related cardiac dysfunction in early-stage HER2 positive breast cancer

Speaker: Doctor G. Oristrell Santamaria (Barcelona, ES)

CerS2 ko in vivo reduces pro-inflammatory ceramides and improves doxorubicin mediated cardiotoxicity

Speaker: Doctor T. Kretzschmar (Jena, DE)

Effect of vitamin D receptor genetic polymorphism on the clinical response to angiotensin converting enzyme inhibitors therapy among breast cancer patients with chemotherapy induced cardiomyopathy

Speaker: Miss I. Al-Ansary (Cairo, EG)

Access the full session

Cardiotoxicity of drugs and other therapies

Speakers: Associate Professor K. Urbanek, Doctor I. Cheang, Mrs G. Muckiene, Doctor G. Oristrell Santamaria, Doctor T. Kretzschmar...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

Initial phase of anthracycline cardiotoxicity involves metabolic switch and activation of cardiac fibroblasts

About the speaker

Associate Professor Konrad Urbanek

6 more presentations in this session

Pre-diabetes is associated with increased cardiac events in cancer patients prescribed anthracyclines

Prognostic value of 6-minute walking test for early prediction of doxorubicin induced cardiotoxicity

Usefulness of the baseline risk assessment guidelines to predict cancer therapy-related cardiac dysfunction in early-stage HER2 positive breast cancer

CerS2 ko in vivo reduces pro-inflammatory ceramides and improves doxorubicin mediated cardiotoxicity

Effect of vitamin D receptor genetic polymorphism on the clinical response to angiotensin converting enzyme inhibitors therapy among breast cancer patients with chemotherapy induced cardiomyopathy

Access the full session

Cardiotoxicity of drugs and other therapies

About the event

ESC Congress 2023

ESC 365 is supported by